← All updates

Apollo Capital Management, L.P. / Apollo Funds

McKesson closes Apollo Funds investment in Medical-Surgical Solutions

June 1, 2026 primary Manager profile

Summary: McKesson announced that it completed the previously announced minority ownership interest investment from funds managed by affiliates of Apollo in McKesson Medical-Surgical Solutions on June 1, 2026. The announcement says Apollo Funds invested $1.25 billion in convertible preferred equity for an approximately 13% interest, while McKesson retained operating control and majority ownership.

Why it matters: The update may matter to due-diligence readers as a public Apollo private-capital activity signal in healthcare distribution and corporate carve-out/separation planning.

9AT filing context: Public ADV/profile context maps the target to Apollo Capital Management, L.P., CRD 143161 / SEC file 801-67592, with about $751.8B in reported regulatory AUM/profile scale, 786 private funds, and public domain apollo.com. No mapped 13F context is recommended for this transaction.

Summary

McKesson announced that it completed the previously announced minority ownership interest investment from funds managed by affiliates of Apollo in McKesson Medical-Surgical Solutions on June 1, 2026. According to McKesson, Apollo Funds invested $1.25 billion in convertible preferred equity for an approximately 13% interest, while McKesson retained operating control and majority ownership.

This item treats McKesson as the primary issuer source for the closing, economics, and ownership-control details. IPO, separation, growth, valuation, and strategic-rationale language should remain attributed to McKesson rather than presented as independent validation by 9AT.

Why it matters

For due-diligence readers, the closing is relevant as a public signal of Apollo-affiliated funds providing structured minority capital to a healthcare distribution business while the issuer remains in operational control. The update may be useful for watching Apollo’s private-capital activity around corporate carve-outs, preferred-equity structures, healthcare services, and sponsor/issuer governance boundaries.

The announcement does not support any conclusion about Apollo fund performance, the future value of McKesson Medical-Surgical Solutions, the likelihood or timing of a separation or IPO, or whether the transaction is attractive for investors. It should not be read as advice about McKesson, Apollo, any Apollo-managed fund, or any security.

Source notes

9AT filing context

Public ADV/profile context maps the target lane to Apollo Capital Management, L.P. in New York, with CRD 143161, SEC file 801-67592, and public website/domain apollo.com. Public profile context used in review reports about $751.8 billion in reported regulatory AUM/profile scale, 10,692 employees, 2,736 advisory employees, 786 private funds, SMA flag true, ERA flag false, and a 2026-04-28 ADV submission.

That context is broad Apollo platform background only. It helps identify the adviser/platform lane, but it does not validate the closing, valuation, separation plan, healthcare strategy, fund-level exposure, preferred-equity terms, or future operating results.

The available 13F filing-history lookup for the matched Apollo profile returned no filer. Even if a separate public 13F mapping were later documented, 13F would generally not be central to this private/minority-interest transaction, so this item omits 13F context.

What to watch

Watch for McKesson, Apollo, rating-agency, regulatory, or future transaction materials that clarify governance rights, separation timing, operating-control changes, use of proceeds, preferred-equity terms, and any additional public disclosures about how Medical-Surgical Solutions is capitalized or positioned after the minority investment.

Source links